| Sep 19 |
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
|
| Sep 19 |
How Edgewise, Up 47%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease
|
| Sep 19 |
Edgewise rises after early trial results for heart disease therapy
|
| Sep 19 |
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
|
| Sep 17 |
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
|
| Sep 17 |
Edgewise jumps ahead of 'key stock-moving event'
|
| Aug 10 |
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
|
| Aug 8 |
Edgewise Therapeutics GAAP EPS of -$0.34 beats by $0.02
|
| Aug 8 |
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 5 |
Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
|
